Fetal and neonatal illnesses caused or influenced by maternal transplacental IgG and/or therapeutic antibodies applied during pregnancy

György Berencsi, Katalin N. Szomor

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The human fetus is protected by the mother's antibodies. At the end of the pregnancy, the concentration of maternal antibodies is higher in the cord blood, than in the maternal circulation. Simultaneously, the immune system of the fetus begins to work and from the second trimester, fetal IgM is produced by the fetal immune system specific to microorganisms and antigens passing the maternal-fetal barrier. The same time the fetal immune system has to cope and develop tolerance and TREG cells to the maternal microchimeric cells, latent virus-carrier maternal cells and microorganisms transported through the maternal-fetal barrier. The maternal phenotypic inheritance may hide risks for the newborn, too. Antibody mediated enhancement results in dengue shock syndrome in the first 8 month of age of the baby. A series of pathologic maternal antibodies may elicit neonatal illnesses upon birth usually recovering during the first months of the life of the offspring. Certain antibodies, however, may impair the fetal or neonatal tissues or organs resulting prolonged recovery or initiating prolonged pathological processes of the children. The importance of maternal anti-idiotypic antibodies are believed to prime the fetal immune system with epitopes of etiologic agents infected the mother during her whole life before pregnancy and delivery. The chemotherapeutical and biological substances used for the therapy of the mother will be transcytosed into the fetal body during the last two trimesters of pregnancy. The long series of the therapeutic monoclonal antibodies and conjugates has not been tested systematically yet. The available data are summarised in this chapter. The innate immunity plays an important role in fetal defence. The concentration of interferon is relative high in the placenta. This is probably one reason, why the therapeutic interferon treatment of the mother does not impair the fetal development.

Original languageEnglish
Title of host publicationMaternal Fetal Transmission of Human Viruses and their Influence on Tumorigenesis
PublisherSpringer Netherlands
Pages281-333
Number of pages53
Volume9789400742161
ISBN (Electronic)9789400742161
ISBN (Print)9400742150, 9789400742154
DOIs
Publication statusPublished - Oct 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Berencsi, G., & Szomor, K. N. (2012). Fetal and neonatal illnesses caused or influenced by maternal transplacental IgG and/or therapeutic antibodies applied during pregnancy. In Maternal Fetal Transmission of Human Viruses and their Influence on Tumorigenesis (Vol. 9789400742161, pp. 281-333). Springer Netherlands. https://doi.org/10.1007/978-94-007-4216-1_9